Business Wire

Kite Lake Sends Letter to Inmarsat Plc Board of Directors Following Letters From Oaktree and Rubric

5.11.2019 18:46:00 EET | Business Wire | Press release

Share

Kite Lake Capital Management (UK) LLP which, as Investment Manager / Sub-Advisor for and on behalf of underlying funds, has an economic interest in 17,770,258 shares (over 3.8% of the outstanding equity) of Inmarsat Plc ("Inmarsat") has today announced that it has sent a letter to the Board of Directors of Inmarsat following earlier letters from Oaktree Capital Management, L.P. and Rubric Capital Management LP.

The full text of the letter is set out below.

The Board of Directors of Inmarsat Plc
99 City Road
London, EC1Y 1AX
UK

5 November 2019

To the Board of Directors of Inmarsat Plc:

Kite Lake Capital Management (UK) LLP (“Kite Lake”), as Investment Manager / Sub-Advisor for and on behalf of underlying funds, has an economic interest in 17,770,258 shares of Inmarsat Plc (over 3.8% of the outstanding equity).

Kite Lake notes the letter published by Oaktree Capital Management (“Oaktree”) on 5 November 2019, and we are in full agreement with the points Oaktree raises. This is an almost unprecedented situation, in which a spectrum asset (“Ligado”), appears to have been ascribed limited to zero value in the analysis of the fairness of the Consortium Scheme price. This is evidenced by the lack of any reference in the Scheme document to Ligado’s potential value, and on the 1Q 2019 Inmarsat Earnings Call held 1st May 2019: To quote CEO Rupert Pearce “… there will be no Ligado revenues in 2019 and we’re not planning for them to return to paying us, anytime in the near future.”

It has since been widely reported that Ligado could very well receive final regulatory approval imminently after over 10 years of delays. This approval is potentially only weeks away, and at the very minimum, we believe that the Board should delay the Scheme hearing until just prior to the Long Stop Date of 10 December 2019 to allow as much time as possible to clarify the regulatory position of Ligado to determine the best course of action with respect to Inmarsat’s current shareholders.

The question we pose to the Board is simple: given the material prospect of regulatory approval prior to the Long Stop Date, would the Board recommend a $7.09 offer if it was made today? We believe the answer should be a categorical no.

We also note the letter of today's date from Rubric Capital Management LP ("Rubric"). Like Rubric, in May 2019, Kite Lake voted for the Scheme, having moved shares owned into “cash” from “swap”, at the expense of the funds managed by Kite Lake at the request of Consortium advisors (on the basis that the vote was expected to be very close). We did so after several discussions with one of the Financial Advisors of the Consortium, with the understanding that if there was a material development with respect to Ligado prior to the Scheme Sanction, the Board would have the ability to either change its recommendation of the Scheme or delay the Scheme hearing.

We believe the Board must do the right thing for existing shareholders and delay the Scheme hearing as long as possible in order to clarify the current state of Ligado. We don’t see any disadvantage to existing shareholders in doing so. The shareholders deserve nothing less.

We note the announcement made by Inmarsat today. If the Board declines to engage with the Oaktree request, Kite Lake’s current intention is to attend the Scheme Hearing, and to indicate our concerns relating to the proposed transaction to the Court.

Sincerely,

Jamie Sherman

Partner

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jamie Sherman
+44 207 052 8310
jamie.sherman@kitelake.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Present New Data on ALYFTREK ® at the North American Cystic Fibrosis Conference9.10.2026 20:15:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine pancreatic function represent a profound shift in how we understand the benefits of treating cystic fibrosis in its earliest stages,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Devel

Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 17:00:00 EEST | Press release

Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Stable Outlook from Fitch Ratings, assigned on 12 June 2026. Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation of the company’s

Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 16:17:00 EEST | Press release

Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magic Quadrant confirms the shift has moved from pilot to boardroom priority. According to Gartner, Visionaries "understands where the market

Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 16:15:00 EEST | Press release

Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The valve features the company’s FREE next generation tissue treatment addressing the two main causes of calcification, phospholipids and aldehydes. Its proprietary LANCELOT advanced manufacturing process includes zero-pressure shaping and laser cutting of

Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale9.10.2026 16:00:00 EEST | Press release

Ada, the pioneer in Agentic Customer Experience, today announced it has achieved the Amazon Web Services (AWS) Travel and Hospitality Competency. The designation recognizes Ada as an AWS Partner with demonstrated technical proficiency and proven customer success helping travel and hospitality brands resolve customer issues at scale. Ada joins a select group of 58 AWS Partners holding the competency, and it reflects a shared commitment to helping travel brands deliver service that holds up on their busiest, most unpredictable days. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009673638/en/ Ada earns AWS Travel and Hospitality Competency for resolving traveler issues at scale "Travel is where agentic customer service gets tested hardest. Demand spikes without warning, policies change by the hour, and customers are often stressed and far from home," said Mike Murchison, CEO and co-founder of Ada. "Our airline and hospitali

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye